Form 4: Amphastar Pharmaceuticals CEO Exercises Stock Options and Reports Beneficial Ownership Changes

Jack Y. Zhang, CEO of Amphastar Pharmaceuticals, exercised stock options and reported changes in beneficial ownership of company stock.

Summary

• On September 13, 2024, Jack Y. Zhang, CEO and Chief Scientific Officer of Amphastar Pharmaceuticals, exercised employee stock options to acquire 100,000 shares of common stock at a price of $14.69 per share.
• Following the transaction, Zhang directly owns 2,633,554 shares of common stock.
• Zhang also indirectly owns 1,229,756 shares through Mary Z. Luo and 6,827,679 shares through Applied Physics and Chemistry Laboratories, Inc.
• Mary Z. Luo, COO, Chief Scientist, and Chairman, also reported these transactions.
• The shares subject to the option are fully vested and immediately exercisable.

Sentiment

Score: 6

Explanation: Neutral sentiment. The document simply reports a transaction. The exercise of options could be seen as a positive sign, but it's a routine filing.

Positives

• The exercise of stock options by the CEO could be interpreted as a positive signal, indicating confidence in the company's future performance.

Industry Context

Form 4 filings are routine disclosures required by the SEC when insiders (officers, directors, and 10% owners) of a publicly traded company buy or sell the company's securities. These filings provide transparency into insider transactions and can be used by investors to gauge management's sentiment about the company's prospects.

Stakeholder Impact

• The transaction may have a minor impact on shareholders as it increases the number of outstanding shares.

Key Dates